High Tide Inc. Completes Acquisition of 51% Stake in Remexian Pharma GmbH

Summary

High Tide Inc. has completed the acquisition of a 51% stake in Remexian Pharma GmbH for €26.4 million, marking its entry into the European cannabis market. The deal includes shares, cash, and loans, with an option to acquire the remaining interest in Remexian after 24 months.Reuters+ 2

Impact Analysis

So basically, High Tide is making a bold move into the European cannabis market by acquiring a majority stake in Remexian Pharma GmbH. This isn’t just about expanding geographically; it’s about diversifying revenue streams and tapping into the lucrative medical cannabis sector in Germany. The timing is interesting—right after a strong Q3 performance, which saw a 7% surge in share price and a return to net profitability.MSN+ 2 The acquisition is priced at a reasonable 3.64 times Annualized Adjusted EBITDA, suggesting High Tide sees significant upside potential.Reuters The market seems to be responding positively, with analysts maintaining a Buy rating despite some overbought signals.Tip Ranks The real play here is the option to acquire the remaining 49% stake, which could further solidify High Tide’s position as a global cannabis player. Watch for how competitors react and any regulatory shifts in the European market.